Skip to main content
Premium Trial:

Request an Annual Quote

Iconix to Perform Toxicogenomic Research for Merck

NEW YORK (GenomeWeb News) - Iconix Pharmaceuticals today said it will use its in vitro toxicogenomic technology to assess drug safety for Merck in the early states of pre-clinical development.
Iconix's in vitro database includes gene-expression profiles on 119 compound treatments on primary rat hepatocytes.
Financial details were not disclosed.